Allergy to pets is a common cause of respiratory allergic diseases. There are limited number of studies evaluating the efficacy of standard antiallergic therapy in patients with epidermal sensitization.

OBJECTIVE

To evaluate the efficacy and safety of using mometasone+olopatadine nasal spray in patients with allergic rhinitis (AR) caused by sensitization to epidermal allergens in continuous exposure of cause significant allergens.

PATIENTS AND METHODS

The study involved 30 adult patients with confirmed AR caused by sensitization to epidermal allergens who had prolonged contact with pet (for at least 8 hours daily). All patients received 25/600 mcg mometasone+olopatadine by 2 doses in each nasal passage twice a day daily during 90 days that corresponds to administration instruction. Evaluation of therapy efficacy and safety was performed taking into account the dynamics of symptoms, results of completion of TNSS, RQLQ and visual analogue scale (VAS) questionnaires and adverse events (AE) registration.

RESULTS

The administration of a fixed combination of mometasone+olopatadine allowed to achieve AR symptoms control and improve life quality in all patients despite continued exposure of cause significant allergens. According to the questionnaires, the TNSS score significantly reduced after 30 days of drug use (0.56 [0; 1.0] scores) compared to the baseline data (2.5 [2.0; 3.0] scores). The total score by VAS before treatment was 70.76 [60; 100] scores, in 1 month after therapy start — 20.5 [10.0; 40.0] scores, in 90 days — 10.8 [0; 40.0] scores. There were no one severe AEs in participants. The most common among other AEs were bloody discharges in 15 (50%) patients, nasal discomfort in 7 (21%) patients. These AEs were considered as non-serious and did not require the prescription of additional therapy.

CONCLUSION

Olopatadine+mometasone spray demonstrated the high efficacy and safety in patients with sensitization to epidermal allergens in the absence of elimination.